Abstract | BACKGROUND: METHODS:
Chemotherapy-naive, TNM Stage IIIB-IV NSCLC patients were randomized to DC ( docetaxel 75 mg/m(2) and cisplatin 75 mg/m(2), d1 q3w), DCb ( docetaxel 75 mg/m(2) and carboplatin area under the concentration-time curve 6 mg/mL.min, d1 q3w), or VC ( vinorelbine 25 mg/m(2), d1, 8, 15, and 22 and cisplatin 100 mg/m(2), d1 q4w). RESULTS: Of 1218 patients, 401 were age > or = 65 years (149/118/134 DC/DCb/VC arms). In the elderly, median survival was 12.6 versus 9.9 months, 1-year survival was 52% versus 41%, 2-year survival was 24% versus 17% for DC versus VC, respectively. DCb survival results were similar to those for VC: median, 9.0 months; 1-year, 38%; 2-year, 19%. Survival outcomes were similar between elderly and younger patients across treatment arms. Compared with younger patients, elderly patients reported moderately higher incidences of NCI CTC (version 1.0) Grade 3-4 asthenia, infection, and pulmonary toxicities across treatment arms, and diarrhea and sensory neurotoxicity for cisplatin-containing arms. Most hematologic toxicities occurred with similar incidences between elderly and younger patients, although neutropenia was slightly increased in elderly patients. CONCLUSION: First-line docetaxel- cisplatin chemotherapy showed similar activity in elderly and younger patients with advanced/metastatic NSCLC; elderly patients tolerated docetaxel- platinum well despite experiencing slightly more toxicity than younger patients.
|
Authors | Chandra P Belani, Frank Fossella |
Journal | Cancer
(Cancer)
Vol. 104
Issue 12
Pg. 2766-74
(Dec 15 2005)
ISSN: 0008-543X [Print] United States |
PMID | 16288485
(Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2005 American Cancer Society. |
Chemical References |
- Taxoids
- Docetaxel
- Vinblastine
- Cisplatin
- Vinorelbine
|
Topics |
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality, pathology)
- Cisplatin
(administration & dosage)
- Docetaxel
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Lung Neoplasms
(drug therapy, mortality, pathology)
- Male
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Staging
- Risk Assessment
- Survival Analysis
- Taxoids
(administration & dosage)
- Treatment Outcome
- Vinblastine
(administration & dosage, analogs & derivatives)
- Vinorelbine
|